Are stem cells a viable treatment option for knee osteoarthritis?


Find a surgeon

The Find a Surgeon directory is a listing of active Fellows of the Royal Australasian College of Surgeons who meet the requirements of the College's Continuing Professional Development (CPD) Program and have opted to be on the list. This list excludes retired or inactive Fellows.


7 November 2016

Treatment of osteoarthritis (OA) utilising mesenchymal stem cells (MSCs) has become a focus of interest according to a report in the latest issue of the Australia and New Zealand Journal of Surgery (ANZJS), the peer-review publication of the Royal Australasian College of Surgeons (RACS).

OA is a degenerative disease that causes pain, stiffness and decreased function and the article poses the question ̶ could the use of MSCs be a legitimate treatment option?

The report suggests that the successful regeneration of cartilage could represent a new minimally invasive, non-surgical alternative to microfracture and subchondral drilling.

Presently, there are various treatment options for OA including those that are reserved for defects less than 2-3cm² and in patients younger than 40 years of age.

MSCs are adult stem cells found in human tissue including bone marrow and fatty tissue (adipose).

Once matured, the stem cells are injected into the damaged joint or embedded into the area of defect.

According to the article patients have reported improvement in symptoms using this method.

Authors of a study mentioned in the article have reported encouraging results from the use of MSCs with platelet-rich-plasma and arthroscopic lavage or cleansing, however say that it is not possible to determine whether the improvements are due to the MSCs alone.

Implantation of MSCs might be a viable treatment alternative for patients suffering from knee OA, but the authors say there is no published clinical data on the long-term outcomes and complications of this treatment or the ideal dose of MSC therapy.

Some Australian clinics are reportedly using MSC therapy to treat advanced knee OA although the issue of safety has not yet been established and the National Medical Research Council has so far not recommended the use of MSCs for the treatment of knee OA.

The article says that patients ultimately need to make their own informed decisions and medical practitioners have a responsibility to ensure that patients understand the potential risks prior to any treatment.

Download full media release (PDF 125KB)